Artal Group Sa Stake in Biomarin Pharmaceutical (Call) (BMRN) Has Increased by $9.00 Million as Valuation Declined; South Street Advisors Decreased Its Stake in Ultimate Software Group (ULTI) by $2.93 Million

November 15, 2017 - By Vivian Park

South Street Advisors Llc decreased its stake in Ultimate Software Group Inc (ULTI) by 28.08% based on its latest 2017Q2 regulatory filing with the SEC. South Street Advisors Llc sold 13,975 shares as the company’s stock rose 8.03% with the market. The institutional investor held 35,790 shares of the technology company at the end of 2017Q2, valued at $7.52M, down from 49,765 at the end of the previous reported quarter. South Street Advisors Llc who had been investing in Ultimate Software Group Inc for a number of months, seems to be less bullish one the $5.92B market cap company. The stock increased 0.19% or $0.37 during the last trading session, reaching $198.37. About shares traded. The Ultimate Software Group, Inc. (NASDAQ:ULTI) has risen 10.74% since November 15, 2016 and is uptrending. It has underperformed by 5.96% the S&P500.

Artal Group Sa increased its stake in Biomarin Pharmaceutical Inc (Call) (BMRN) by 200% based on its latest 2017Q2 regulatory filing with the SEC. Artal Group Sa bought 100,000 shares as the company’s stock declined 0.71% while stock markets rallied. The institutional investor held 150,000 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $13.62M, up from 50,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Biomarin Pharmaceutical Inc (Call) for a number of months, seems to be bullish on the $14.30 billion market cap company. The stock increased 0.43% or $0.35 during the last trading session, reaching $81.41. About shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.29% since November 15, 2016 and is uptrending. It has underperformed by 11.41% the S&P500.

South Street Advisors Llc, which manages about $326.54 million and $305.11 million US Long portfolio, upped its stake in Medtronic Plc (NYSE:MDT) by 99,550 shares to 112,509 shares, valued at $9.99M in 2017Q2, according to the filing. It also increased its holding in Pulte Group Inc (NYSE:PHM) by 406,770 shares in the quarter, for a total of 447,040 shares, and has risen its stake in Valvoline Inc.

Among 25 analysts covering Ultimate Software (NASDAQ:ULTI), 16 have Buy rating, 1 Sell and 8 Hold. Therefore 64% are positive. Ultimate Software had 53 analyst reports since October 22, 2015 according to SRatingsIntel. On Thursday, October 12 the stock rating was maintained by Mizuho with “Hold”. The firm earned “Buy” rating on Wednesday, October 28 by Deutsche Bank. The firm earned “Outperform” rating on Thursday, October 22 by RBC Capital Markets. As per Thursday, July 27, the company rating was maintained by KeyBanc Capital Markets. The stock of The Ultimate Software Group, Inc. (NASDAQ:ULTI) earned “Buy” rating by Canaccord Genuity on Sunday, October 29. RBC Capital Markets maintained the stock with “Buy” rating in Sunday, September 3 report. The company was upgraded on Monday, October 31 by Wedbush. As per Monday, September 11, the company rating was maintained by Robert W. Baird. The rating was maintained by Wells Fargo with “Buy” on Thursday, November 2. The company was maintained on Thursday, April 28 by Wedbush.

More notable recent The Ultimate Software Group, Inc. (NASDAQ:ULTI) news were published by: Businesswire.com which released: “Ultimate Software’s Vivian Maza Named One of the Top HR Executives in the US” on November 10, 2017, also Valuewalk.com with their article: “Market Share Matters Little When Profits Are Disappearing” published on October 24, 2017, Seekingalpha.com published: “Ultimate Software: Market Share Matters Little When Profits Are Disappearing” on November 01, 2017. More interesting news about The Ultimate Software Group, Inc. (NASDAQ:ULTI) were released by: Businesswire.com and their article: “Ultimate Software Reveals Xander AI Platform for HCM and Comprehensive Partner …” published on October 17, 2017 as well as Seekingalpha.com‘s news article titled: “Ultimate Software Group (ULTI) CEO Scott Scherr on Q3 2017 Results – Earnings …” with publication date: November 03, 2017.

Investors sentiment increased to 1.07 in Q2 2017. Its up 0.14, from 0.93 in 2017Q1. It is positive, as 34 investors sold ULTI shares while 88 reduced holdings. 37 funds opened positions while 94 raised stakes. 32.89 million shares or 3.97% more from 31.63 million shares in 2017Q1 were reported. Nelson Roberts Advsrs Ltd reported 0% stake. Walleye Trading Limited Liability Corp holds 0% or 1,061 shares. 115 are owned by Global X Mgmt Ltd Liability Corp. Texas-based United Automobile Association has invested 0.01% in The Ultimate Software Group, Inc. (NASDAQ:ULTI). Macquarie Gp Ltd invested in 10,712 shares or 0% of the stock. Yorktown Mgmt And Incorporated accumulated 0.1% or 1,500 shares. Profund Ltd owns 3,703 shares. Moreover, Goldman Sachs has 0.03% invested in The Ultimate Software Group, Inc. (NASDAQ:ULTI) for 517,015 shares. Invesco Ltd holds 0.02% or 376,909 shares in its portfolio. United Cap Advisers Llc stated it has 0% of its portfolio in The Ultimate Software Group, Inc. (NASDAQ:ULTI). Mutual Of America Capital Management has 23,794 shares. Shine Investment Advisory Serv Inc holds 40 shares. Strs Ohio invested in 77,500 shares or 0.07% of the stock. Millennium Mgmt Ltd Limited Liability Company invested in 47,878 shares. First Mercantile accumulated 2,386 shares.

Analysts await The Ultimate Software Group, Inc. (NASDAQ:ULTI) to report earnings on February, 6. They expect $0.12 earnings per share, down 72.09% or $0.31 from last year’s $0.43 per share. ULTI’s profit will be $3.58M for 413.27 P/E if the $0.12 EPS becomes a reality. After $0.17 actual earnings per share reported by The Ultimate Software Group, Inc. for the previous quarter, Wall Street now forecasts -29.41% negative EPS growth.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Globenewswire.com which released: “BioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market …” on October 16, 2017, also Fool.com with their article: “BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal” published on November 01, 2017, Seekingalpha.com published: “BioMarin Pharmaceutical (BMRN) Q3 2017 Results – Earnings Call Transcript” on October 27, 2017. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Nasdaq.com and their article: “BioMarin Pharmaceutical is Now Oversold (BMRN)” published on November 14, 2017 as well as Seekingalpha.com‘s news article titled: “BioMarin: No Short-Term Catalysts, Slowing Revenue Growth” with publication date: October 25, 2017.

Artal Group Sa, which manages about $5.72 billion US Long portfolio, decreased its stake in Chemocentryx Inc (NASDAQ:CCXI) by 46,278 shares to 500,000 shares, valued at $4.68M in 2017Q2, according to the filing. It also reduced its holding in Sarepta Therapeutics Inc (Call) (NASDAQ:SRPT) by 200,000 shares in the quarter, leaving it with 100,000 shares, and cut its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY).

Investors sentiment increased to 1.26 in 2017 Q2. Its up 0.06, from 1.2 in 2017Q1. It improved, as 23 investors sold BMRN shares while 124 reduced holdings. 51 funds opened positions while 134 raised stakes. 168.09 million shares or 1.78% more from 165.15 million shares in 2017Q1 were reported. Thrivent Financial For Lutherans stated it has 170,905 shares or 0.06% of all its holdings. Comml Bank Of New York Mellon reported 0.06% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Citadel Advsr Ltd holds 242,021 shares. Rice Hall James And Associates Ltd owns 9,770 shares or 0.04% of their US portfolio. Capstone Asset Mgmt holds 0.02% or 7,458 shares in its portfolio. Bb&T invested in 0.02% or 12,778 shares. Los Angeles Capital Equity Rech holds 33,194 shares or 0.02% of its portfolio. Blair William & Il accumulated 0.07% or 97,540 shares. Moody Fincl Bank Trust Division invested 0.02% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Marshall Wace Limited Liability Partnership holds 13,606 shares or 0.05% of its portfolio. 21,091 were accumulated by Bnp Paribas Arbitrage Sa. 694,828 are held by Voya Inv Llc. Axa invested in 0.17% or 402,257 shares. Numeric Invsts Ltd has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 16,100 shares. The Netherlands-based Shell Asset Com has invested 0.05% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Since May 17, 2017, it had 0 buys, and 8 insider sales for $5.08 million activity. 1,004 shares were sold by Ajer Jeffrey Robert, worth $89,968. BIENAIME JEAN JACQUES sold $901,300 worth of stock or 10,000 shares. Another trade for 9,471 shares valued at $862,230 was made by Davis George Eric on Monday, June 5. LAWLIS V BRYAN sold 3,750 shares worth $337,500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.